Cape Town Conference Centre Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2007



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Challenges of Global Vaccine Development (T1)


Organizer(s) Margaret Liu, Paul-Henri Lambert and Sir Gustav Nossal
October 8—13, 2007
Cape Town Conference Centre • Cape Town, South Africa
Abstract Deadline: Jun 6, 2007
Late Abstract Deadline: Jul 11, 2007
Scholarship Deadline: Jun 6, 2007
Early Registration Deadline: Aug 8, 2007

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation and the Wellcome Trust

Summary of Meeting:
Despite the tremendous impact of vaccines to save countless lives, significant scientific and technical barriers exist that limit both their effectiveness against many diseases and their utilization, resulting in millions of needless deaths and substantial morbidity particularly in the developing world. Even with the large increase of our understanding of host immune responses, the sequencing of pathogen genomes, and other technological advances, important hurdles remain for developing and deploying vaccines for a variety of diseases. The goals of this meeting will be to bring together scientists, physicians and students from the developed and developing world to discuss the advances in (1) understanding the generation of effective systemic and mucosal immunity at a cellular and organ system level, (2) new technologies for prophylactic and therapeutic immunization, including those useful for resource-poor settings, (3) understanding the unique requirements to stimulate immunity in early childhood, (4) pre-clinical models, and (5) correlates of protection.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


MONDAY, OCTOBER 8

15:00—19:30
Registration

Strelitzia
18:30—19:30
Welcome Reception

Day Restaurant
19:30—19:50
Welcome and Orientation

Auditorium 2
* Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA
The Unique Scientific and Real-World Challenges of Global Vaccine Development

19:50—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Regina N. Rabinovich, ISGlobal, Spain / Harvard T.H. Chan School of Public Health, USA, Spain
The Challenges of Translation of Vaccine Research into Impact


TUESDAY, OCTOBER 9

07:00—08:00
Breakfast

Day Restaurant
08:00—11:30
Population Differences in Immune Responses to Vaccines and Implications for Childhood and Pandemic Diseases
Meeting has ended...abstracts no longer viewable online.

Auditorium 2
* Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA

* Gustav Nossal, University of Melbourne, Australia

* Paul-Henri Lambert, University of Geneva, Switzerland

Myron M. Levine, University of Maryland School of Medicine, USA
Differences in Immune Responses in Different Populations

Hazel M. Dockrell, London School Hygiene & Tropical Medicine, UK
BCG Vaccination Induces Different Immune Responses in Malawian and UK Vaccinees

Willem A. Hanekom, Bill & Melinda Gates Foundation, USA
BCG-Induced Immune Correlates of Protection Against Tuberculosis

Anne E. Goldfeld, Children's Hospital Boston, Harvard Medical School, USA
HIV/TB Host-Pathogen Interactions

09:20—09:40
Coffee Break

Day Restaurant
11:30—12:00
Poster Setup

Day Restaurant
12:00—14:00
Luncheon with Grand Challenges in Global Health Meeting

Ballroom
Harold E. Varmus, Weill Cornell Medical College, USA

Bishop Desmond Tutu, Former Archbishop of Cape Town, South Africa

Graça Machel, , South Africa

Tadataka Yamada, Mountain Field LLC, USA

14:30—16:30
Workshop 1A Devoted to Specific Diseases that Overwhelm the Developing World: Malaria

Auditorium 2
* Michal Fried, Seattle Biomedical Research Institute, USA

* Stefan Kappe, Seattle BioMed, USA

Dominic Kwiatkowski, Wellcome Trust Centre for Human Genetics, UK
Learning from the Human Genome How Protective Immunity Against Malaria Works

Patrick E. Duffy, NIAID, National Institutes for Health, USA
Protective Immunity Against Severe Malaria in Young Children

Adrian V. S. Hill, Jenner Institute, University of Oxford, UK
Vectored Vaccines for Malaria

Salim Abdulla, Ifakara Health Institute, Tanzania
Malaria Vaccine Clinical Trials in Africa

14:30—16:30
Workshop 2A on Vaccine Technologies: Stability of Vaccines

Roof Terrace Room
* Marie-Paule Kieny, World Health Organization, Switzerland

Colin R. Gardner, TransForm Pharmaceuticals, Inc., USA
Increasing Vaccine Stability through Novel Technology

Claire M. Coeshott, GlobeImmune, Inc., USA
Thermostable Vaccines with Improved Stability at Non-Refrigerated Temperatures

Yoshikazu Yuki, Institute of Medical Science, Japan
Development of Needle- and Cold-Chain-Free Vaccine: Rice-Based Oral Vaccine

16:30—17:00
Coffee Available

Day Restaurant
17:00—19:30
Effector vs. Memory Responses
Meeting has ended...abstracts no longer viewable online.

Auditorium 2
* Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA

* Carolyn Williamson, University of Cape Town, South Africa

Rafi Ahmed, Emory University School of Medicine, USA
Manipulating Regulatory T Cell in the Development of Vaccines or Translating Innate Immunity into Immunologic Memory: Implications for Vaccine Development

Rudolf A. Manz, Deutsches Rheuma-Forschungszentrum, Germany
Plasma Cell Niches: Molecular Determinants of Long-Lived Plasma Cells

Kenneth Smith, University of Cambridge, UK
The Inhibitory Fc Receptor FcgammaRIIb, Immune Responses, Autoimmunity and Malaria

George M. Shaw, University of Pennsylvania, USA
Identification of the Transmitted HIV-1 Envelope and Its Evolution in Acute and Early Human Infection

19:30—20:30
Social Hour with Lite Bites

Day Restaurant
20:00—22:00
Poster Session 1

Day Restaurant

WEDNESDAY, OCTOBER 10

07:00—08:00
Breakfast

Day Restaurant
08:00—11:30
Innate and Adaptive Immune Responses/Adjuvants
Meeting has ended...abstracts no longer viewable online.

Auditorium 2
* Souleymane Mboup, Universite Cheikh Anta DIOP, Senegal

* Marie-Paule Kieny, World Health Organization, Switzerland

Paul-Henri Lambert, University of Geneva, Switzerland
Towards Effective and Safe Vaccines: Assessing the Risk-Benefit Ratio of Activating Innate Immunity

Alan Aderem, Center for Infectious Disease Research, USA
A Systems Approach to Vaccine Development

Eyal Raz, University of California, San Diego, USA
Irradiated Pathogens to Activate Dendritic Cells via TLRs for the Induction of T Cell Responses

David C. Jackson, University of Melbourne, Australia
The Use of Simple Synthetic Lipid Structures for Targeting Different Vaccine Cargos to Dendritic Cells

Peter Andersen, Statens Serum Institut, Denmark
TB Vaccine - Pre/Post Exposure

09:20—09:40
Coffee Break

Day Restaurant
11:00—12:00
Poster Setup

Day Restaurant
11:30—00:30
Lunch

Day Restaurant
12:30—14:30
Poster Session 2

Day Restaurant
14:30—16:30
Workshop 1B Devoted to Specific Diseases that Overwhelm the Developing World: Tuberculosis Vaccines

Auditorium 2
* Martin Ota, Medical Research Council, Gambia

* Jerald C. Sadoff, Crucell Vaccine Institute, Janssen Pharmaceutical Companies of Johnson & Johnson, Netherlands

Tom H. M. Ottenhoff, Leiden University Medical Center, Netherlands
Results from a Safety and Immunogenicity Clinical Trial with an Adjuvanted Ag85/ESAT6 Subunit Vaccine against Tuberculosis

Helen McShane, Jenner Institute, UK
MVA85A - An Update on Clinical Trials

Greg D. Hussey, University of Cape Town, South Africa
BCG and Clinical Trails

Leander Grode, Vakzine Projekt Management, Germany
Developing a TB Vaccine for Human Use

Francois Spertini, Centre Hospitalier Universitaire Vaudois, Switzerland
Safety and Immunogenicity of the Mtb72F/AS02A Tuberculosis Vaccine

Megan Murray, Harvard Medical School, USA
Modeling of Clinical TB

14:30—16:30
Workshop 2B on Vaccine Technologies: Needle Free Delivery, Aerosol Delivery and Nanoparticles

Roof Terrace Room
* Sujit Kuman Bhattacharya, National Institute of Cholera and Enteric Diseases, India

Ana Maria Henao-Restrepo, World Health Organization, Switzerland
Development of a Measles Aerosol Vaccine

David A. Edwards, Harvard University, USA
Dry Powder Nanoparticle Inhaled Aerosols for Needle-Free Vaccination

Robert E. Sievers, University of Colorado, USA
Needle-Free Delivery of Stable, Respirable Dry Powder Measles Vaccine Formulations

James R. Baker Jr., University of Michigan, USA
Naoemulsions as Adjuvants for Nasal-Spray Vaccines

David D. Lo, University of California, Riverside, USA
Development of a Targeted Mucosal Vaccine Delivery Technology

16:30—17:00
Coffee Available

Day Restaurant
17:00—19:30
Neonatal and Infant Immunity
Meeting has ended...abstracts no longer viewable online.

Auditorium 2
* Claire-Anne Siegrist, University of Geneva, Switzerland
Challenges and Perspectives for Optimal Early Life Vaccine Responses

Lorne A. Babiuk, University of Alberta, Canada
Linking Innate and Specific Immunity to Develop Single-Dose Vaccines for Neonates

Victoria J. Philbin, xx, USA
Distinct Function of Toll-Like Receptors (TLRs) in Human Neonatal Antigen-Presenting Cells: Unique Potential of TLR8 Agonists as Neonatal Vaccine Adjuvents

Martha Sedegah, Naval Medical Research Center, USA
Immunological Responses of Neonates and Infants to DNA-Based Vaccines

Mustafa Akkoyunlu, US Food And Drug Administration, USA
Differences in Adult and Neonatal BAFF/APRIL System: Implications for Polysaccharide Vaccines


THURSDAY, OCTOBER 11

07:00—08:00
Breakfast

Day Restaurant
08:00—11:15
Vaccines Impacting on Microbial Ecology
Meeting has ended...abstracts no longer viewable online.

Auditorium 2
* Luis Jodar, International Vaccine Institute, South Korea

* Stefan H. E. Kaufmann, Max Planck Institute for Infection Biology, Berlin, Germany

Richard Adegbola, Bill & Melinda Gates Foundation, USA
Haemophilus influnzae type b (Hib) Conjugate Vaccine: Clinical Trials and Implementation of an Effective Routine Hib Immunization Programme in The Gambia

Helena Käyhty, National Public Health Institute, Finland
The Use of Nasopharyngeal Carriage as an End Point for Efficacy Trials and Registration and Use of New Pneumococcal Vaccine Formulations

Shabir Madhi, National Institute for Communicable Diseases, South Africa
Pneumococcal Conjugate Vaccine in Developing Countries: Potential for Addressing the Ignored Epidemic

Jonathan Carapetis, Telethon Institute for Child Health Research, Australia
Global Burden of Group A Streptococcal Disease, and Progress in Vaccine Development

John D. Clemens, International Vaccine Institute, South Korea
New Approaches to the Assessment of Vaccine Herd Immunity and Herd Protection

11:15—11:30
Special Announcement
Meeting has ended...abstracts no longer viewable online.
Dr. Jose Esparza, Senior Advisor on HIV Vaccines for the Bill & Melinda Gates Foundation, will announce an important new development in the growth of the Global HIV Vaccine Enterprise, an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine. Originally proposed in 2003, the purpose of the Enterprise is to build consensus in the HIV vaccine field on scientific priorities, mobilize new resources to implement these priorities, and facilitate the rapid sharing of information that can advance the field as a whole. To date, the Enterprise has mobilized more than $750 million in support of its scientific plan.

09:20—09:40
Coffee Break

Day Restaurant
11:30—12:00
Poster Setup

Day Restaurant
11:30—12:30
Lunch

Day Restaurant
12:30—14:30
Poster Session 3

Day Restaurant
14:30—16:30
Workshop 1C Devoted to Specific Diseases that Overwhelm the Developing World: HIV Vaccines

Auditorium 2
* Glenda Gray, South African Medical Research Council, South Africa

Blake Ball, University of Manitoba, Canada
Comprehensive Studies of Mechanisms of HIV Resistance in Highly Exposed Uninfected Women

George K. Lewis, University of Maryland, USA
Targeting Co-receptor Steps for Protective Immunity Against HIV-1

Hongkui Deng, Peking University, China
Development of Novel Mouse Models for HIV and HCV Infection

Rudi Balling, Centre for Systems Biology Luxembourg, University of Luxembourg, Luxembourg
Novel Mouse Models for Testing HIV and HCV Vaccines

Michael Ott, Hannover Medical School, Germany
Novel Mouse Models for Testing HIV and HCV Vaccines

14:30—16:30
Workshop 1D: Enteric Pathogens

Roof Terrace Room
* John D. Clemens, International Vaccine Institute, South Korea

Firdausi Qadri, International Centre for Diarrhoeal Disease Research, Bangladesh
Mucosal Immunity to Common Enteric Pathogens and Relevance to Vaccine Development

Sujit Kuman Bhattacharya, National Institute of Cholera and Enteric Diseases, India
Field Trial of Enteric Vaccines in Kolkata

Gregory M. Glenn, Novavax, USA
Transcutaneous Immunization with LT: Development of a Needle-Free Vaccine Patch

16:30—17:00
Coffee Available

Day Restaurant
17:00—19:30
Mucosal and Dermal Vaccines and Immunity
Meeting has ended...abstracts no longer viewable online.

Auditorium 2
* Gustav Nossal, University of Melbourne, Australia

Charles J. Arntzen, Biodesign Institute, Arizona State University, USA
Progress in Plant-Made Vaccines

Robin Shattock, Imperial College London, UK
Novel Antigen Design and Delivery for Mucosal Protection Against HIV-1 Infection

Roy Curtiss III, Arizona State University, USA
A Live Recombinant Attenuated Salmonella Anti-Pneumococcal Vaccine for Newborns

Béhazine Combadière, INSERM, France
Short Talk: Follicular Targeting: From Skin Explant to Transcutaneous Vaccination in Humans


FRIDAY, OCTOBER 12

07:00—08:00
Breakfast

Day Restaurant
08:00—11:45
Correlates of Immunity in Pre-Clinical Models and Clinical Studies
Meeting has ended...abstracts no longer viewable online.

Auditorium 2
* Glenda Gray, South African Medical Research Council, South Africa

Stefan H. E. Kaufmann, Max Planck Institute for Infection Biology, Berlin, Germany
Towards Characterization of Protective Immunity against TB

Markus G. Manz, University Hospital Zürich, Switzerland
A Mouse Model to Evaluate Live Attenuated Vaccine Candidates

Britta E. Wahren, Karolinska Institute, Sweden
Progress of the HIV Vaccine Phase I/II Immunogenicity Study (HIVIS Project) in Dar es Salaam, Tanzania: HIV-1 DNA Plasmid Prime and MVA Boost

Sarah L. Rowland-Jones, Oxford University, UK
Long-Term Non-Progression with HIV Infection: Lessons from HIV-2

Carolyn Williamson, University of Cape Town, South Africa
Multigene Human Immunodeficiency Virus Type 1 Subtype C DNA and Modified Vaccinia Ankara (MVA) Vaccine

* Gary J. Nabel, Sanofi, USA
Development and Evaluation of a T-Cell Based Multi-Clade AIDS Vaccine

09:20—09:40
Coffee Break

Day Restaurant
14:30—16:30
Workshop 3: Issues for Introducing Vaccines to Developing Countries: Coordination of Clinical Trials in Different Populations and Markets, Access, Vaccine Cost, Affordability, and Financing

Auditorium 2
* José G. Esparza, Bill & Melinda Gates Foundation, USA

Bernard Fourie, Medicine in Need, South Africa
Challenges to Vaccine Access in High-Burden Settings

Duncan Steele, PATH, USA
Delivering Rotavirus Vaccines to Impact the Millennium Development Goals

Jean Stephenne, GlaxoSmithKline Biologicals, Belgium
GSK Issues for Global Vaccine Manufacturers

Luis Jodar, International Vaccine Institute, South Korea
Translational Research to Assist Policy Decisions about Introducing New Vaccines into Developing Countries

Carl E. Frasch, Frasch Biologics Consulting, USA
Strategies for Production of Pneumococcal Conjugate Vaccines in and for Developing Countries

14:30—16:30
Workshop 2C on Vaccine Technologies and Other Novel Technologies: Mucosal and Dermal Vaccines

Roof Terrace Room
* Britta E. Wahren, Karolinska Institute, Sweden
Novel Delivery Devices and Approaches for Immunization

* Rachel Chikwamba, Council for Scientific and Industrial Research (CSIR), South Africa
Plant Derived Vaccines for Mucosal Delivery

Edward P. Rybicki, University of Cape Town, South Africa
Plant-Produced Vaccines: Promise and Reality

Philippe E. Laurent, Becton Dickinson, France
Evaluation of the Clinical Performance of BD™ Microinjection System for Intradermal Vaccine Delivery

16:30—17:00
Coffee Available

Day Restaurant
17:00—18:30
Novel Approaches to Immunity
Meeting has ended...abstracts no longer viewable online.

Auditorium 2
* Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA

* Gustav Nossal, University of Melbourne, Australia

Reinhard Kurth, Ernst Schering Foundation, Germany
Novel Approaches to Flu Vaccine Development

Abraham L. Sonenshein, Tufts University, School of Medicine, USA
Bacterial Spores as Heat-Stable Vaccine Delivery Systems

Lennart Hammarström, Karolinska Institute, Sweden
Passive Immunity via Orally-Administered lactobacilli

18:30—19:30
Concluding Keynote Address
Meeting has ended...abstracts no longer viewable online.

Auditorium 2
Anna-Lise Williamson, University of Cape Town, South Africa
Vaccine Development: An Essential Part of Health Security in Africa

19:30—20:30
Social Hour with Lite Bites

Day Restaurant
20:00—23:00
Entertainment

Day Restaurant

SATURDAY, OCTOBER 13

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI076090-01




We gratefully acknowledge additional support for this conference from:

Becton Dickinson Bill & Melinda Gates Foundation
Wellcome Trust
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



BD Medical Pharmaceutical Systems


Genentech, Inc.


GlaxoSmithKline Biologicals


IOMAI Corporation


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676